Abstract The discovery of a novel non-AT 1 , non-AT 2 binding site for angiotensins in the rodent brain and testis that is unmasked by the organomercurial compound para-chloromercuribenzoic acid (PCMB) has catalyzed efforts to purify and characterize this protein. We recently reported that this protein is neurolysin and now report upon the specificity of this binding site for various neuropeptides. Competition binding assays in rat brain and testis used 125
Introduction
Research studies have long determined that angiotensin II (Ang II) plays a significant role in the development of cardiovascular disease and hypertension. According to the Centers for Disease Control and Prevention, the leading cause of death in the U.S. in 2010 was heart disease (595,444 deaths) and the fourth leading cause was cerebrovascular disease (129,180 deaths) (http://www.cdc.gov/nchs/data/nvsr/nvsr60/ nvsr60_04.pdf, accessed October 4, 2012) . Ang II is a major effector octapeptide, critical for the maintenance of blood pressure and plasma Na ? concentration. The primary role of the renin-angiotensin system (RAS) in the body is to maintain blood volume and electrolyte balance. Dysregulation of the RAS causes several pathophysiological states, of which hypertension is most prominent [1] .
Dysregulation can result from altered redox state in the bloodstream which can increase the conversion of angiotensinogen to Ang I [2] . Overexpression of renin, as well as prorenin, also increases Ang I formation. In the classic RAS, angiotensin-converting enzyme (ACE) then converts Ang I into Ang II, the major effector peptide of the RAS. Its wellknown roles include stimulation and release of aldosterone, leading to retention of sodium and an increase in blood pressure by vascular smooth muscle contraction and increased sympathetic outflow. In addition, excessive demand on the heart leads to hypertrophy while direct effects of Ang II on the heart cause fibrosis which compromises cardiac output. Stress on vascular cell walls combined with proinflammatory effects of Ang II lead to an increased deposition of plaque on blood vessel walls leading to atherosclerosis [3] . Ang II exerts these effects primarily on the angiotensin II type I (AT 1 ) subtype receptor. Ang II is further converted to the heptapeptide Ang III by glutamyl aminopeptidase A. Ang III, which also acts upon the AT 1 subtype, is then converted to the hexapeptide Ang IV by the cleavage of the Arg at its N-terminal by membrane alanyl aminopeptidase N [4] . Ang IV binds to a pleiotropic protein known as the AT 4 receptor, insulin-regulated aminopeptidase, vasopressinase, and oxytocinase (E.C. 3.4.11.3) [5] .
A novel angiotensin-binding protein, distinct from the known receptors for angiotensin peptides was discovered in the rat brain [6, 7] . It is membrane bound, unmasked in the presence of para-chloromercuribenzoic acid (PCMB), not N-glycosylated, does not behave similar to the most G proteincoupled receptors, including the AT 1 receptor, and has an isoelectric point of *7 [8] . In addition, it has been localized in mouse testis and other structures [9] . These studies led to the identification of this binding site as the metallopeptidase neurolysin (E.C. 3.4.24.16) [10] . Of note, a soluble angiotensin-binding protein isolated from porcine liver [11] was later shown to be neurolysin [12] , which has 90 % homology to rat neurolysin and 91 % homology to mouse neurolysin. While the latter study [10] of the angiotensin-binding protein was in progress, the present study examined the ability of this protein to interact with other brain peptides, analogs of Ang II, and a putative dipeptide inhibitor of neurolysin.
Materials and methods

Tissue preparation
Male Sprague-Dawley rats were sacrificed with fluorothane inhalation and brains and testes were harvested, frozen at -20°C and subsequently stored at -80°C. The frozen rat brains and testes were weighed and homogenized for 5-10 s in 25 mL of ice-cold, 20 mM NaPO 4 , pH 7.4 (hypotonic buffer) by a mechanical homogenizer. Homogenates were centrifuged at 40-48,0009g for 20 min and the supernatants were decanted. The membrane pellets were resuspended by homogenization for 5-10 s in the assay buffer AM5 (150 mM NaCl, 5 mM EDTA, 0.1 mM bacitracin, 50 mM NaPO 4 ). The homogenates were recentrifuged as before. The final pellet was resuspended in AM5 to give a tissue concentration of 50 mg/mL (initial wet wt.). AT 1 and AT 2 blockers, PD 123319 and Losartan (each having a final concentration of 10 lM), and PCMB (final concentration of 100 lM) were added to the tissue homogenate approximately 10 min before incubation. Tissue was kept on ice prior to incubation at room temperature. Animal procedures were approved by the IACUCs of Nova Southeastern University and the University of Florida. [13] . Membrane bound 125 I-SI Ang II was collected on glass fiber filters prewetted with 1 mg/mL bovine serum albumin using a cell harvester (Model M24R, Brandel, Gaithersburg, MD). Incubation tubes and filters were rinsed three times with 50 mM NaKPO 4 , pH 7.4 to minimize nonspecific binding to the filters. Bound radioligand maintained on the filter disks was assayed with a COBRA II gamma counter. For three of the peptides that exhibited [50 % inhibition of specific 125 I-SI Ang II binding at 10 lM, as well as proline-isoleucine dipeptide (Pro-Ile), reported to be specific for neurolysin [14] , secondary screenings were performed at five different concentrations ranging from 0.1 lM up to 1 mM. Log IC 50 was determined by nonlinear regression curve fitting of % inhibition of specific binding data to a one-site competition model algorithm constrained for 100 % specific binding (Prism,Graphpad Software, San Diego, CA). Graphical representation of the data also used Prism software. Values presented are averages ± SEM. Statistical comparisons of Log IC 50 values between brain and testis were based on 95 % confidence intervals (Table 1) .
Results
Primary screening of 36 peptides, endocrine peptides, angiotensin-related peptides, the putative substrates for the AT 4 receptor (vasopressin and oxytocin), the putative neurolysin specific inhibitor, Pro-Ile, and Plummer's inhibitor, revealed seven peptides with IC 50 values \10 lM for both brain and testis ( 
Discussion
The main purpose of this study was to further characterize the pharmacological specificity of the novel non-AT 1 , non-AT 2 binding site in the rodent brain and testis [6, 9] which has been subsequently identified as neurolysin [10] . Competitive binding assays were performed using 36 different peptides and a specific peptidase inhibitor to determine whether this binding site is specific for angiotensins or if it has broader ligand/substrate specificity. Primary screening of the 36 peptides showed only S36057, orphanin FQ and its analogs, ghrelin, dynorphin A (1-8), and angiotensin (1-9) to inhibit [50 % at 10 lM in both brain and testis. Secondary screenings performed on three of these peptides indicated IC 50 values between 1 and 10 lM, except for orphanin FQ in the brain which was slightly [10 lM. All tested peptides (Table 1) are grouped according to physiological relevance. Orphanin FQ, also known as nociceptin is a heptadecapeptide which has a primary structure reminiscent of that of opioid peptides [15] and has structural homology with the dynorphin family [16] . Orphanin FQ is an endogenous ligand that also inhibits adenylyl cyclase activity. The name nociceptin was derived from its ability to induce enhanced reactivity to noxious thermal stimuli. Studies on rats have shown that orphanin FQ decreases systemic arterial pressure in a dose-related manner [17] . Tyr 1 orphanin FQ, an analog of nociceptin, was also found to behave similarly in terms of vasodepressor activity and potency [16] .
Ghrelin is a 28 amino acid peptide that acts as an endogenous orexigenic hormone. This peptide is widely distributed in various tissues, such as the intestines, hypothalamus, and pancreas, along with its mRNA. Studies have also shown ghrelin to have multiple biological functions, including vasodilation and energy homeostasis [18] . S36057 has been classified as a potent ligand for the melanin-concentrating hormone receptor [19] . Melaninconcentrating hormone also has orexigenic actions, as well as reproductive and stress-related signaling activity [20] .
The amino acid sequences of orphanin FQ, ghrelin and S36057 do not reveal a recognition motif identical to known neurolysin cleavage sites [21] [22] [23] , however, these peptides like most neurolysin substrates are primarily basic, and have aromatic amino acids and/or prolines. Given the extensive diversity of amino acids that can mimic the P 3 , P 2 , P 1 , P 1 0 , P 2 0 and P 3 0 sites of the substrates of neurolysin, these peptides might easily be previously unidentified substrates of neurolysin.
Dynorphin A (1-8), first 5 amino acids of which contain the structure of leucine-enkephalin, is reported to be a substrate of neurolysin [23] [24] [25] [26] . Dynorphin A (1-8) is reported to be cleaved at the 5-6 bond by neurolysin to form the endogenous opioid peptide leucine-enkephalin [23, 25, 26] . As such, only five amino acids must be accommodated in the putative substrate binding channel (as described from its crystal structure [22] ) distal to the active site.
Angiotensin (1-9) is a likely substrate of neurolysin in view of the high affinity binding of Ang I and Ang II to this protein [6] . Angiotensin (1-9) is formed by the action of angiotensin-converting enzyme 2 (ACE2) albeit at a relatively slow rate compared to the formation of Ang (1-7) from Ang II [27, 28] . It is not certain whether neurolysin forms Ang (1-7) or Ang (1-4) and Ang (5-9) from Ang (1) (2) (3) (4) (5) (6) (7) (8) (9) . If the cleavage site is at the 4-5 bond, then only four amino acids must be accommodated in the putative substrate binding channel [22] distal to the active site. In contrast, the 3-7 fragment of Ang II showed negligible inhibition of 125 I-SI Ang II binding in brain and testis, consistent with a previous observation in mouse brain [7] . This suggests that the arginine 2 at the P 3 position relative to neurolysin is of critical importance for Ang II binding. It is noteworthy that the acidic carboxy terminal of PCMB has the potential to form an ionic bond with a basic amino acid, such as arginine. This potential for ionic bond formation may be compromised by the aspartic acid 1 of Ang II based upon the higher binding affinities of Ang III and Sar 1 , Ile 8 Ang II for this protein relative to Ang II [6, 7] . In addition, the Ang (3-7) and (1-9) data suggests that having a phenylalanine or isoleucine as the carboxy terminal amino acid at the P 4 0 position is also critical to high affinity binding of Ang II to neurolysin.
In contrast, several neuropeptides reported to be substrates for neurolysin; urocortin, neuromedin B [29] , and somatostatin [23, 30] inhibited 125 I-SI Ang II binding \25 % at a concentration of 10 lM. Of note, there is one report claiming that human neurolysin does not metabolize somatostatin [31] . Orexin B, which is also reported to be a substrate of neurolysin [29] displayed a slightly greater inhibition of 125 I-SI Ang II binding, 31 and 41 % in brain and testis, respectively. The putative cleavage sites for urocortin, neuromedin B, somatostatin, and orexin B by neurolysin are 13, 9, 6 or 10, and 6 amino acids from the amino terminal of the parent peptide, respectively [23, 29] . This portion of these peptides may not be able to fit into the bottom of the ligand binding channel [22] when PCMB is bound to a cysteine sulfhydryl distal to the active site of neurolysin as proposed (Santos et al., submitted for publication).
Pro-Ile has been characterized as a specific albeit low affinity inhibitor of neurolysin. Its K I is reported to be 90 lM and has been used at concentrations up to 5 mM to selectively inhibit neurolysin activity relative to other endopeptidases [14] . Surprisingly, Pro-Ile did not inhibit 125 I-SI Ang II binding at concentrations up to 1 mM. This observation is reminiscent of previous studies of this non-AT 1 , non-AT 2 binding protein in mouse brain in which it was shown that another neurolysin inhibitor, JA-2, also did not compete for 125 I-SI Ang II binding [7] . Previous studies of the affinity of this PCMB unmasked Ang II binding site for substrates of neurolysin also failed to reveal a specificity characteristic of neurolysin [6] . This suggests that the alteration of neurolysin by PCMB such as to unmask its ability to bind Ang II with high affinity is a pharmacological effect to enhance its affinity for Ang II, while diminishing its affinity for other substrates and ProIle.
Originally described as an inhibitor of angiotensinase C (now known as prolylcarboxypeptidase) [32] , PCMB has also been reported to inhibit the catalytic activity of neurolysin [33] . Neurolysin has been shown to metabolize Ang II as well as Ang I [22, 23, 25, 34, 35] . The products of Ang II metabolism by neurolysin are the inactive, (1-4) and (5-8) fragments of Ang II [22, 23] . The product of Ang I metabolism by neurolysin is Ang (1-7) [25, 36] . By degrading Ang II as well as forming Ang (1-7), neurolysin can antagonize the well-known pathophysiological effects of Ang II mediated by the AT 1 receptor [37] . However, there are two reports [26, 36] that Ang II is not a substrate of neurolysin despite having K I values of 4.9 and 2.4 lM for rat and human neurolysin. This suggests that Ang II could be an endogenous inhibitor of neurolysin. Thus, neurolysin may play an important role in the regulation of the RAS. Conversely, neurolysin may be regulated by the RAS, thereby affecting the functionality of other peptidergic systems in the brain and other tissues. Both mechanisms warrant further study of the interactions of the renin-angiotensin system with neurolysin.
